The Biotech Investor’s Bible
February 23, 2010 by biotechconnection.com · 5 Comments
Product Description
The complete guide to investing in the biotech industry
“Clear, never condescending, and with abundant references to biotech firms and their work in progress, The Biotech Investor’s Bible is a book that had to be written. Essential for the investor, fascinating even for armchair students of the industry, it’s a valuable reference, a guide to what is coming, and an irresistible read . . . it will be a definitive reference in the field.”––Andrew Allentuck, globetechnology.com
“The Biotech Investor’s Bible outlines sensibly and with balance the opportunities and challenges of an industry that will change our lives. A must read guide for the individual investor.”––William A. Haseltine, Ph.D., Chairman, CEO, and Founder, Human Genome Sciences, Inc., Editor-in-chief, E-Biomed: The Journal of Regenerative Medicine
Investors with a practical understanding of biotechnology share a remarkable opportunity: the chance to invest in an industry on the threshold of tremendous growth. With the long-term potential to cure most major diseases and to revolutionize industries as diverse as pharmaceuticals and forestry, petrochemicals and agriculture, the possibilities for biotech––and its investors––are limitless.
The Biotech Investor’s Bible provides you with the strategies and proven techniques to reduce risk and increase returns, including:
- The steps you must know in order to assess the biotech market •
- A comprehensive look at 185 major biotech companies •
- Guidelines to follow when planning your biotech portfolio •
- An overview of the latest biotech therapies and breakthroughs •
- Tips on how to find sound and promising companies in the sector •
- An easy-to-understand introduction to the science and technology in the field •
Order from Amazon –> The Biotech Investor’s Bible
At last a book that makes some sense of the biotech sector! The author, George Wolff has a very straightforward approach, starting with the big picture of the industry’s development and then getting down to specifics about market behavior such as the reasons for the sector’s incredible volatility. Wolff’s analysis involves breaking the sector down in Four Tiers. Each behaves somewhat differently with the lowest Tier being both the riskiest and the cheapest to buy into. Tier One encompasses the well-known majors such as Amgen, which are relatively safe but less exciting plays. I think Wolff has set out a framework of understanding that allows investors to discriminate among the companies to find a reasonable balance of growth potential and security. Most of the book is strictly about investment analysis but the second part of it (Book 2) tries to decode the scientific background. I like his analogy, comparing the workings of DNA and cellular machinery to the innards of a computer. It’s a clear enough explanation to convince me that I finally understand this abstract stuff. All in all, a good, illuminating read for people like me who are interested in the industry and where it’s going. The investment advice is sensible and has a reasonable tone….not a “get rich quick book.” I know there’s another book on the market that looks strictly at the medical side of the biotech business. I like the fact the Wolff has gone beyond that to look at the ways the industry can affect a lot of other major sectors such as energy, chemicals, textiles and so on. Wolff believes biotech is going to become the biggest industry in the world and now that I see where the industry is headed, I think he’s right.
Rating: 5 / 5
The Biotech Investors Bible is the first advice on biotech investing that doesn’t seem simplistic. I’m tired of jumping on the high tech bandwagons touted by soundbits on TV or sidebars in magazines. I’m ready to dip my feet into the water of what seems a more promising industry. The Biotech Investors’ Bible gives me the depth of knowledge that inspires real confidence for the first time in my investing career. I TRUST IT!
Rating: 5 / 5
At last a book that makes some sense of the biotech sector! The author, George Wolff has a very straightforward approach, starting with the big picture of the industry’s development and then getting down to specifics about market behavior such as the reasons for the sector’s incredible volatility. Wolff’s analysis involves breaking the sector down in Four Tiers. Each behaves somewhat differently with the lowest Tier being both the riskiest and the cheapest to buy into. Tier One encompasses the well-known majors such as Amgen, which are relatively safe but less exciting plays. I think Wolff has set out a framework of understanding that allows investors to discriminate among the companies to find a reasonable balance of growth potential and security. Most of the book is strictly about investment analysis but the second part of it (Book 2) tries to decode the scientific background. I like his analogy, comparing the workings of DNA and cellular machinery to the innards of a computer. It’s a clear enough explanation to convince me that I finally understand this abstract stuff. All in all, a good, illuminating read for people like me who are interested in the industry and where it’s going. The investment advice is sensible and has a reasonable tone….not a “get rich quick book.” I know there’s another book on the market that looks strictly at the medical side of the biotech business. I like the fact the Wolff has gone beyond that to look at the ways the industry can affect a lot of other major sectors such as energy, chemicals, textiles and so on. Wolff believes biotech is going to become the biggest industry in the world and now that I see where the industry is headed, I think he’s right.
Rating: 5 / 5
Good review of the various biotech subsectors and future biotech trends. The book compares biotech to the PC industry and gives a fairly good insight about what might happen from an industrial and investing perspective.
Rating: 5 / 5
I read dozens of investment books. I have never read one that is as cogent and helpful as The Biotech Investor’s Bible. It has signiificantly helped me develop a realistic criteria for choosing which biotech stocks to invest in. It will have a permant place on my shelf of investment books.
Rating: 5 / 5